Gilead Reports 61 Clinical Programs Under Way, With Over 20 In Phase III

Excluding Veklury, Core Product Sales Grow

 
• By Alaric DeArment
  
Gilead reported its first quarter 2023 earnings on 27 April • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business